BHB-1893

N/A

Report date: 2026/05/12 20:00:17
NME

Base Information

Drug NameBHB-1893
Drug Alias Name(S)-6-((1-(2-fluoro-5-methylphenyl)ethyl)amino)-3-(tetrahydro-2H-pyran-4-yl)-1,3,5-triazine-2,4(1H,3H)-dioneHRS-1893HRS1893BHB-1893BHB1893
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCardiac myosin inhibitors
TargetsCardiac myosin
Therapy Area/IndicationsHeart Failure, DiastolicHeart FailureCardiomyopathy, Hypertrophic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShandong Shengdi Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBraveheart Bio IncAtridia Pty LtdShandong Shengdi Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsHeart Failure, DiastolicHeart FailureCardiomyopathy, Hypertrophic +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A